Therefore, Mel can be used as a potential cardio-protective adjuvant in DCM therapy and down-regulation of VEGF-B/GRP78/PERK signaling pathway will be a promising modality for clinical DCM therapy. This evidence concerns the gene HSPA5 and familial dilated cardiomyopathy.